<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Age-adjusted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence and age-related penetrance studies have helped guide <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk assessment and management </plain></SENT>
<SENT sid="1" pm="."><plain>PTEN <z:hpo ids='HP_0010566'>hamartoma</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> syndrome (PHTS) is a term encompassing subsets of several clinical syndromes with germline mutations in the PTEN <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted the first prospective study to clarify corresponding <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks to shed biologic insights on human germline PTEN mutations, and to better inform current surveillance recommendations on the basis of expert opinion </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: A series of 3,399 individuals meeting relaxed International Cowden Consortium PHTS criteria were prospectively recruited; 368 individuals were found to have deleterious germline PTEN mutations </plain></SENT>
<SENT sid="4" pm="."><plain>Age-adjusted standardized incidence ratio (SIR) calculations and genotype-phenotype analyses were carried out </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Elevated SIRs were found for <z:mp ids='MP_0002038'>carcinomas</z:mp> of the breast [25.4, 95% confidence interval (CI), 19.8-32.0], thyroid (51.1, 38.1-67.1), endometrium (42.9, 28.1-62.8), colorectum (10.3, 5.6-17.4), kidney (30.6, 17.8-49.4), and <z:hpo ids='HP_0002861'>melanoma</z:hpo> (8.5, 4.1-15.6) </plain></SENT>
<SENT sid="6" pm="."><plain>Estimated lifetime risks were, respectively, 85.2% (95% CI, 71.4%-99.1%), 35.2% (19.7%-50.7%), 28.2% (17.1%-39.3%), 9.0% (3.8%-14.1%), 33.6% (10.4%-56.9%), and 6% (1.6%-9.4%) </plain></SENT>
<SENT sid="7" pm="."><plain>Promoter mutations were associated with <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, whereas <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> was associated with nonsense mutations </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Lifetime risks for a variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, now extending to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:e sem="disease" ids="C0740457" disease_type="Neoplastic Process" abbrv="">kidney cancer</z:e>, and <z:hpo ids='HP_0002861'>melanoma</z:hpo>, are increased in patients with PTEN mutations </plain></SENT>
<SENT sid="9" pm="."><plain>The genotype-phenotype associations here may provide new insights on PTEN structure and function </plain></SENT>
<SENT sid="10" pm="."><plain>We propose a comprehensive approach to surveillance of patients with PTEN mutations </plain></SENT>
</text></document>